top of page

Imophoron announces formation of its Scientific Advisory Board of renowned experts in the vaccine field

BRISTOL, UK --20/06/2022—Imophoron Ltd, a biotechnology company pioneering a disruptive vaccine technology based on its proprietary nanoparticle platform, ADDomer™, today announces the formation of its Scientific Advisory Board (SAB). The SAB is comprised of internationally renowned experts in infectious diseases, the vaccine industry and public health.  The SAB will work closely with Imophoron’s leadership team to provide external scientific review and high-level counsel on the company’s vaccine research and development programs.

Professor Imre Berger, Chairman of the SAB, who was recently elected Fellow of the Academy of Medical Sciences, added: ‘I am immensely proud to have this stellar group of academic and industrial movers and shakers on the Imophoron SAB. Each member brings leading know-how and unique insights to Imophoron and we are delighted that we could attract such expertise to our board.’

Frederic Garzoni, Chief Executive Officer of Imophoron Ltd, commented: ‘We are thrilled to announce the official inauguration of Imophoron’s SAB. We are honoured to welcome these leading experts in immunology, drug discovery and development, and look forward to their scientific and strategic guidance to help advance our ADDomer™  vaccine programs. I am certain that Imophoron will benefit greatly from their individual and collective expertise.’

Imophoron’s Scientific Advisory Board is comprised of:

Professor Adam Finn -  is a Professor of Paediatrics at the University of Bristol, Head of the Bristol Children’s Vaccine Centre and Director of the recent Pfizer Vaccine Centre of Excellence. He is Chairman of the WHO European Technical Advisory Group of Experts (ETAGE) on Immunization, since 2011, and a member of the UK Department of Health Joint Committee on Vaccination and Immunisation (JCVI), since 2014. In 2015, he was elected President of the European Society for Paediatric Infectious Diseases (ESPID).

Dr Helen Bright – is VP of R&D at Centauri Therapeutics and a biopharmaceutical professional and leader with over 25 years of industry experience. She is a leading expert in infectious diseases, immunology and vaccines and has a proven track record of advancing novel small molecules, biologics and vaccine candidates from discovery to the clinic (Investigational New Drug, Biologics License Applications,  Marketing Authorisation Application submissions).

Paul Edwards MBE – is currently Managing Partner Global Healthcare at Horton International and Director at OBN (UK) Ltd. He has spent over 30 years in the pharmaceuticals and life sciences sector, working initially with Beecham Pharmaceuticals, before joining Genzyme Corporation, where he headed the company’s UK operations  In 2000, he joined the UK based biosimilars’ organisation, GeneMedix plc as Chief Executive Officer, and successfully led a major funding round taking the company to a dual listing on the London and Singapore Stock Exchanges.

Professor Lisa Ng -­­ is a renowned immunologist and expert on infectious diseases including zika, Covid, hepatitis and influenza. She is currently Executive Director of A*STAR’s Biomedical Research Council (BMRC), and holds a concurrent appointment as Executive Director at A*STAR’s Infectious Diseases Laboratories, where she focuses on the immune responses to arthritic arboviruses that are epidemic ,or highly endemic, in the tropical region.

Dr Bassam Hallis - is Deputy Director of UK Health Security Agency and has over 25 years of experience in scientific research in infectious diseases and vaccines and 20 years in regulated activities including vaccine evaluation, release/stability and clinical trial serology. He has extensive experience in assay development and validation including cell-based and functional assays as well as technology transfer of early-stage and validated tests.

Professor Imre Berger – is Chair of Imophoron’s SAB, Professor of Chemistry and Biochemistry at the University of Bristol, Director of the Max Planck Bristol Centre for Minimal Biology and Director of the Bristol Synthetic Biology Centre BrisSynBio. His career of 25+ years spans synthetic biology, structural biology and biotech. Before joining Bristol, he worked and taught at Massachusetts Institute of Technology (USA), ETH Zurich (Switzerland) and EMBL (France). He publishes prolifically in leading periodicals including Nature and Science.


About Imophoron       

Imophoron Ltd is a pre-clinical stage biotechnology company developing a novel class of vaccines, referred to as ADDomers™, for infectious diseases where people are either underserved or not currently protected by existing vaccines. ADDomers™ are fully synthetic nanoparticles which self-assemble into a stable structural geometry, which in addition is thermostable. The structure allows for multiple epitope insertion, in several loops, which induces a significant immune response with high selectivity, making ADDomers™ attractive candidates for vaccine development. Early pre-clinical studies have demonstrated the ability for intra-nasal and intramuscular routes of administration. Imophoron is developing IMN-100, a vaccine candidate for Respiratory Syncytial Virus; IMN-200, a vaccine candidate for COVID-19, which has the potential as a pan-coronavirus vaccine; and IMN-300, a vaccine candidate for Chikungunya. Imophoron was founded in 2017 and is headquartered in Bristol, UK, with laboratories at the Science Creates, Old Market Incubator. For more information, visit


For further information please email;

bottom of page